China Grand Pharmaceutical and Healthcare Holdings Limited

Money comes in through outright, one-time sales of manufactured goods, booked once a customer takes delivery, rather than through subscriptions, licensing, or usage-based fees, with its pharmaceutical-technology and biotechnology lines generating most of that revenue and its nuclear-medicine and interventional line a smaller share. The large majority of sales are earned inside one domestic market, with a modest share coming from customers abroad.

Its own account describes growth coming through two channels used together: buying and absorbing other pharmaceutical and biotechnology businesses in its recent history, and building new manufacturing capacity of its own. Separately, CompanyGraph's recomputed financial history shows revenue, gross profit, and net income each expanding or staying positive across every recent year on file.

Its own filings name a supplier, Yuanda Jiufu, for raw materials behind its steroid-hormone and related products, plus a second supplier relationship tied to products it distributes through named exclusive partners, and describe manufacturing as done in its own plants rather than through named outside contractors. Its own risk disclosures also flag a geographic and currency dependency, since most operations and transactions sit inside one country and one currency with no currency hedging in place at its last year end, and it depends on holding a wide set of national certifications to keep selling into the markets it exports to.

Its own disclosures say no single customer accounts for a large share of revenue in the years reported, so its downstream base is spread across many buyers rather than concentrated in one, though one relationship is named directly: Huadong Medicine and its related companies, which buy pharmaceutical preparations, raw materials, and related services from it. Beyond that, its buyers are described broadly as hospitals, primary healthcare institutions, and pharmacies, without a breakdown of how much each group represents.

CompanyGraph places this company among a very large group of companies, hundreds of them, that run the same kind of system: manufacturing product that must clear a regulatory approval step before it earns anything, making this a common way of operating rather than a rare one. Separately, the company states its own claimed position within one specific niche, saying it holds more registered amino-acid active ingredients than any other pharmaceutical company in its home market, though neither observation says anything about whether rivals could copy what it does, which is not something CompanyGraph can see.

Its own account does not describe a contract, backlog, or retention mechanism that would make switching away difficult for its customers. It explicitly frames its wide set of product certifications and registrations as a compliance and market-access foundation rather than something that binds customers to it, and it books revenue as one-time sales rather than through the kind of ongoing contracts that typically create switching costs.

The kind of business this company is classified under is generally shaped by a regulatory approval step that a product must clear before it earns anything, which is CompanyGraph's starting assumption about this line of business rather than a measurement of this specific company, and its own account sits a little uneasily with a simple version of that story since it already earns revenue across several product families sold into many outlets at once rather than waiting on one pending approval. Nothing in its own account states what it considers the actual limit on its scale, whether that is manufacturing capacity, an input, or specialized staff, so CompanyGraph does not make that claim.

Its own risk disclosures put market risk first among the pressures it names, ahead of currency, interest-rate, liquidity, operational, and investment risk, and separately name a geographic and currency concentration as a specific exposure, since most of its operations and transactions sit inside one country and one currency with no currency hedging in place at its last year end. Its own figures separately rule out a different common vulnerability, since no single customer accounted for a large share of revenue in the years disclosed, and the one legal matter it discloses is described as resolved in its favor.

Its own risk disclosures name market risk first among the pressures it identifies, ahead of foreign-exchange, interest-rate, liquidity, operational, and investment risk, and it answers to a national medicines regulator, with one business line, radiopharmaceuticals, carrying its own separate production, operation, and radiation-safety licensing. Because most of its operations and transactions sit inside one country and one currency with no currency hedging in place at its last year end, it names currency movements as a pressure with a possible financial effect, and selling into a wide range of other countries also means holding a wide set of national certifications that its filings frame as a compliance and market-access requirement.